FDA Accepts Eisai’s Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Source Cluster: JCN Newswire Source Node: 1981422Time Stamp: Jun 10, 2024